NCT05988008

A Study of CCX168 in Japanese and Caucasian Healthy Adult Males

A Phase I Clinical Study of CCX168 in Japanese and Caucasian Healthy Adult Males

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 80 (actual)
• Sponsor: Amgen · Industry
• Sex: Male
• Age: 20 Years – 45 Years
• Healthy volunteers: Accepted

Summary

The objectives of the study will be to investigate the safety and pharmacokinetics of a single oral administration and a twice-daily multiple oral administration of CCX168 in Japanese healthy adult males; and to compare the pharmacokinetics of a single oral administration and a twice-daily multiple oral administration of CCX168 between Japanese and Caucasian healthy adult males.

Conditions

• Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis

Interventions

Type	Name	Description
DRUG	CCX168	Administered orally.
DRUG	Placebo	Administered orally.

Timeline

• Start date: 2017-10-23
• Primary completion: 2018-01-26
• Completion: 2018-09-20
• First posted: 2023-08-14
• Last updated: 2023-08-14

Locations

1 site across 1 country: Japan

Regulatory

• FDA-regulated drug study